Articles related to ANTIDEPRESSANTS

In an adaptive randomized trial of adults with long COVID, fluvoxamine modestly reduced fatigue and improved quality-of-life scores through 90 days, while metformin findings remained inconclusive after dose modification and early termination.

A systematic review of 12 studies found that vortioxetine consistently improved depressive symptoms in adults aged 65 years and older with major depressive disorder, but evidence for cognitive benefits remained mixed and largely confined to selected cognitive domains.

In a longitudinal analysis of more than 167,000 children in Wales, maternal depression was associated with higher rates of special educational needs and neurodevelopmental disorders. Additional risk observed among antidepressant-exposed pregnancies remained difficult to separate from underlying depression severity.

A comprehensive prescribing guide argues that orally administered racemic ketamine may offer a low-cost, accessible option for severe, suicidal, or treatment-resistant depression, while emphasizing structured protocols, monitoring, informed consent, and careful patient selection.

Physical symptoms following antidepressant cessation are generally transient and consistent with established discontinuation phenomena, while persistent or delayed symptoms remain difficult to explain pharmacodynamically and may involve psychiatric, psychological, or somatic contributors.

Emerging reports suggest some patients experience emotional blunting or reduced reward responsiveness after starting GLP-1 receptor agonists. Current evidence remains mixed, and available data have not established a causal relationship between GLP-1 therapy and diminished antidepressant response.